Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Part of paid clinical trials in Bethesda, Maryland.
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Study ID
- NCT06676033
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Leukemia, Chronic Lymphocytic
- Richter Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- epcoritamab — DRUGSamples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Study Details
This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHLBI) investigators are experienced in testing samples treated with bsAb2,3 including epcoritamab in an ongoing pre-clinical collaboration with Genmab. Addressing the objectives of this correlative study will advance the science and clinical application of epcoritamab specifically as well as T-cell engaging bsAb in general as an emerging class of immunotherapy for cancer. The study is enrolling by invitation only.
Key Dates
- Start date
- Jul 18, 2025
- Status verified
- Feb 2026
- Primary completion
- Jul 1, 2027
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: epcoritamabSamples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Primary Outcome Measure
Immunophenotype and transcriptome of T cells and tumor cells in lymph node and bone marrow [ Time Frame: 25 days (Cycle 1 Day 25) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | - |
Find similar trials in Bethesda, MD
Related Studies
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaPHASE1/PHASE2 · Recruiting · New York Medical College · Valhalla, New York
- Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's TransformationPHASE2 · Recruiting · Weill Medical College of Cornell University · New York, New York
- Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPHASE2 · Recruiting · Mayo Clinic · Palo Alto, California
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).PHASE3 · Recruiting · Merck Sharp & Dohme LLC · Springdale, Arkansas